PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
Biologics. 2012; 6: 337–345.
Published online Sep 25, 2012. doi:  10.2147/BTT.S26558
PMCID: PMC3459550
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Kim-Son H Nguyen and Joel W Neal
Stanford Cancer Institute, Stanford University, Stanford, CA, USA
Correspondence: Joel W Neal, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA, Tel +1 650 725 3081, Fax +1 650 498 5800, Email jwneal/at/stanford.edu
Received September 24, 2012
Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line therapeutic options in patients with tumors harboring activating mutations in the EGFR gene. The TKIs are better tolerated than conventional chemotherapy, with frequent yet mild side effects such as rash and diarrhea, and rarely interstitial lung disease. Because most patients on TKIs develop resistance due to a variety of mechanisms, the use of TKIs in the acquired-resistance setting and in the setting of earlier-staged cancers is being extensively studied. Here we review the major trials leading to the established use of EGFR TKIs in NSCLC, followed by discussion of recently completed and ongoing trials using the next-generation EGFR inhibitor afatinib.
Keywords: epidermal growth factor receptor, non-small-cell lung cancer, tyrosine kinase inhibitor, epidermal growth factor receptor mutation
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press